Enrollment Completed for Phase 3 Trial Evaluating 1404 Radioactive Imaging Agent

Enrollment Completed for Phase 3 Trial Evaluating 1404 Radioactive Imaging Agent
Progenics Pharmaceuticals has completed enrollment in the Phase 3 study assessing its PSMA-targeted imaging agent 1404 as a tool to identify prostate cancer patients with clinically significant disease. “The results of this large-scale Phase 3 study will provide important insights on the potential of our novel imaging agent to accurately and non-invasively detect and monitor patients with low-grade prostate cancer,” Mark Baker, CEO of Progenics, said in a press release. “We believe that 1404 has the possibility to transform the practice of active surveillance, and we look forward to providing top-line results in the third quarter.” 1404 is a molecular imaging agent designed to target the prostate specific membrane antigen (PSMA), a protein that is found in 95 percent of prostate cancer cells. The molecule also contains the radioactive isotope Technetium-99m, allowing it to be seen in single-photon emission computed tomography (SPECT). When bound to the PSMA protein, 1404 is expected to provide a sensitive and accurate image of the localization and concentration of prostate cancer cells. The tool may enable more precise biopsies and targeted strategies to manage the disease. The proSPECT-AS trial (NCT02615067) includes 450 men with newly-diagnosed or low-grade prostate cancer. Pa
Subscribe or to access all post and page content.